Article
Medicine, Research & Experimental
Cristina Bouzas, Rosario Pastor, Silvia Garcia, Margalida Monserrat-Mesquida, Miguel Angel Martinez-Gonzalez., Jordi Salas-Salvado, Dolores Corella, Albert Goday, J. Alfredo Martinez, Angel M. Alonso-Gomez, Olga Fernandez-Barcelo, Jesus Vioque, Dora Romaguera, Jose Lopez-Miranda, Ramon Estruch, Francisco J. Tinahones, Jose Lapetra, Lluis Serra-Majema, Blanca Riquelme-Gallegop, Vicente Martin-Sanchez, Xavier Pinto, Miguel Delgado-Rodriguez, Pilar Matia, Josep Vidal, Jersy-Jair Cardenas-Salas, Lidia Daimiel, Emilio Ros, Estefania Toledo, Josep M. Manzanares, Inmaculada Gonzalez-Monge, Miguel-Angel Munoz, Diego Martinez-Urbistondo, Lucas Tojal-Sierra, Carlos Munoz-Bravoaf, Salvador Miralles-Gisbert, Marian Martin, Antonio Garcia-Rios, Sara Castro-Barquero, Jose Carlos Fernandez-Garcia, Jose Manuel Santos-Lozano, F. Javier Basterra-Gortari, Liliana Gutierrez-Carrasquilla, Patricia Guillem-Saiz, Alba Satorres, Itziar Abete, Carolina Sorto-Sanchez, Javier Diez-Espino, Nancy Babio, Montse Fito, Josep A. Tur
Summary: In a one-year study involving 6881 patients with MetS, it was found that those treated with GLP-1RA and DPP-4I had better glycemic profiles, but improvements in weight and waist circumference were modest.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Public, Environmental & Occupational Health
Richeek Pradhan, Elisabetta Patorno, Helen Tesfaye, Sebastian Schneeweiss, Hui Yin, Jessica Franklin, Ajinkya Pawar, Christina Santella, Oriana H. Y. Yu, Christel Renoux, Laurent Azoulay
Summary: The study compared GLP-1 receptor agonists users with different active comparator groups and found a modestly increased risk of anaphylactic reaction associated with GLP-1 RAs.
AMERICAN JOURNAL OF EPIDEMIOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Yi-Hsin Chan, Tze-Fan Chao, Shao-Wei Chen, Hsin-Fu Lee, Pei-Ru Li, Wei-Min Chen, Yung-Hsin Yeh, Chi-Tai Kuo, Lai-Chu See, Gregory Y. H. Lip
Summary: The study evaluated the risk of new-onset AF associated with SGLT2i, GLP-1RA, and DPP4i in patients with type 2 diabetes, and found that SGLT2i, but not GLP-1RA, was associated with a lower incidence of AF compared to DPP4i.
CARDIOVASCULAR DIABETOLOGY
(2022)
Review
Endocrinology & Metabolism
Yijun Li, Ying Hu, Xiaoyuan Huyan, Kang Chen, Bing Li, Weijun Gu, Yiming Mu
Summary: The study aims to analyze the efficacy and safety of three novel hypoglycemic agents, GLP-1 RAs, DPP-4i, and SGLT2i, in T2DM patients with severe CKD. The results show that SGLT2i performs better than placebo and DPP-4i in reducing the incidence of severe renal-related adverse events and renal death. Compared to placebo, SGLT2i also significantly reduces the incidence of all-cause death and severe adverse events, while DPP-4i significantly reduces HbA1c levels.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Yaping Du, Lei Bai, Bingge Fan, Haixia Ding, Haiyan Ding, Lin Hou, Hongfang Ma, Na Xing, Fujun Wang
Summary: The study compared the contribution of SGLT2 inhibitors to lower extremity amputation rates with that of DPP4 or GLP-1 inhibitors, finding that SGLT2 inhibitors were not significantly superior to other anti-hyperglycemic agents in terms of diabetic foot-related limb amputations.
PRIMARY CARE DIABETES
(2022)
Article
Pharmacology & Pharmacy
Andreana Foresta, Luisa Ojeda-Fernandez, Giulia Macaluso, Maria Carla Roncaglioni, Mauro Tettamanti, Ida Fortino, Olivia Leoni, Stefano Genovese, Marta Baviera
Summary: This study assessed the effect of dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) on COVID-19-related outcomes. The results showed a reduced risk of COVID-19 total mortality in DPP-4i users compared with nonusers. Additionally, GLP-1 RA users had a lower hospital admission rate and SGLT-2i users had a lower in-hospital mortality rate compared with nonusers. Randomized clinical trials are needed to confirm the potential therapy of these drug classes for COVID-19 treatment.
CLINICAL THERAPEUTICS
(2023)
Review
Urology & Nephrology
Nuria Montero, Laia Oliveras, Maria Jose Soler, Josep Maria Cruzado
Summary: PTDM is a common issue after kidney transplantation, affecting 50% of high-risk recipients. KDIGO has updated guidelines for diabetes management in CKD, focusing on newer antidiabetic agents. Generating evidence is necessary to safely use these treatments and evaluate their potential cardiovascular and renal benefits in PTDM patients.
CLINICAL KIDNEY JOURNAL
(2022)
Article
Endocrinology & Metabolism
Donna Shu-Han Lin, Jen-Kuang Lee, Wen-Jone Chen
Summary: The study revealed that in patients with type 2 diabetes, the use of GLP1RAs was associated with significantly lower risks of major adverse limb events compared to DPP4is. The reduction in risk was primarily due to decreased rates of amputations.
Article
Gastroenterology & Hepatology
Santo Colosimo, Federico Ravaioli, Maria L. Petroni, Lucia Brodosi, Francesca Marchignoli, Francesca A. Barbanti, Anna S. Sasdelli, Giulio Marchesini, Loris Pironi
Summary: The study showed that GLP-1 receptor agonists and SGLT-2 inhibitors can improve biomarkers of steatosis and fibrosis, therefore slowing down the progression of liver disease.
LIVER INTERNATIONAL
(2021)
Review
Medicine, General & Internal
Shuyan Gu, Xiaoqian Hu, Lizheng Shi, Xuemei Zhen, Xueshan Sun, Minzhuo Huang, Yuxuan Gu, Hengjin Dong
Summary: This study compared the efficacy of various glucose-lowering drugs as initial monotherapy for type 2 diabetes. The results showed that sulfonylureas were the most effective in reducing HbA1c and fasting plasma glucose, but increased the risk of hypoglycemia. Glucagon-like peptide-1 receptor agonists were the most effective in reducing BMI and total cholesterol. Thiazolidinediones were the most effective in increasing high-density lipoprotein cholesterol. Sodium-glucose cotransporter-2 inhibitors were the most effective in lowering systolic blood pressure. However, alpha-glucosidase inhibitors were associated with a higher risk of discontinuation due to adverse events. GLP-1RAs showed an integrated beneficial effect on all outcomes.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Behavioral Sciences
Che-Yuan Wu, Lila Shapiro, Michael Ouk, Bradley J. MacIntosh, Sandra E. Black, Baiju R. Shah, Walter Swardfager
Summary: Type 2 diabetes is a major risk factor for dementia. Different glucose-lowering drugs have different effects on the brain. The current clinical and epidemiological data are mixed, requiring careful evaluation. Personalized strategies using glucose-lowering drugs have great potential in preventing and treating dementia.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
(2022)
Article
Chemistry, Medicinal
In Sun Goak, Jin A. Lee, Min Ho Jeong, Seol Ju Moon, Min Gul Kim
Summary: This study compared the pharmacokinetics of two fixed-dose combination (FDC) formulations in healthy Korean subjects. The results showed that the test FDC drug was equivalent to the reference FDC drug and both formulations were safe and well tolerated.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2022)
Article
Endocrinology & Metabolism
Jui Wang, Hon-Yen Wu, Kuo-Liong Chien
Summary: This study found that DPP4 inhibitors have better cardioprotective effects compared to sulfonylureas in preventing major adverse cardiovascular events. Sitagliptin and vildagliptin showed a significantly lower risk of hospitalization, while saxagliptin showed a borderline significantly higher risk of hospitalization for heart failure.
DIABETES & METABOLISM
(2022)
Article
Pharmacology & Pharmacy
Yen-Chieh Lee, Yaa-Hui Dong, Wei-Shun Yang, Li-Chiu Wu, Jou-Wei Lin, Chia-Hsuin Chang
Summary: The study found that the use of SGLT-2i in patients with type 2 diabetes does not increase the risk of hospitalization for limb events compared to GLP-1RA. However, a trend of higher LEA risk was observed among SGLT-2i users with a history of cardiovascular disease.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Mingtong Xu, Kan Sun, Wenjie Xu, Chuan Wang, Dewen Yan, Shu Li, Li Cong, Yinzhen Pi, Weihong Song, Qingyuan Sun, Rijun Xiao, Weixia Peng, Jianping Wang, Hui Peng, Yawei Zhang, Peng Duan, Meiying Zhang, Jianying Liu, Qingmei Huang, Xuefeng Li, Yan Bao, Tianshu Zeng, Kun Wang, Li Qin, Chaoming Wu, Chunying Deng, Chenghu Huang, Shuang Yan, Wei Zhang, Meizi Li, Li Sun, Yanjun Wang, Hongmei Li, Guang Wang, Shuguang Pang, Xianling Zheng, Haifang Wang, Fujun Wang, Xiuhai Su, Yujin Ma, Wei Zhang, Ziling Li, Zuoling Xie, Ning Xu, Lin Ni, Li Zhang, Xiangqun Deng, Tianrong Pan, Qijuan Dong, Xiaohong Wu, Xingping Shen, Xin Zhang, Qijing Zou, Chengxia Jiang, Jue Xi, Jianhua Ma, Jingchao Sun, Li Yan
Summary: The study aimed to evaluate the efficacy and safety of a novel DPP-4 inhibitor, fotagliptin, in treatment-naive patients with T2DM. The results demonstrated that fotagliptin was non-inferior to alogliptin in improving glycemic control, with significantly more patients in the fotagliptin and alogliptin groups achieving HbA1c < 7.0% after 24 weeks of treatment.